The Increasing Prevalence of Respiratory Diseases in the World Is Boosting the Market Growth

 

Respiratory Inhalers Market

Respiratory Inhalers Market, By Product Type (Dry Powder Inhaler Metered Dose Inhaler Nebulizer (Ultrasonic Nebulizer, Compressed Air Nebulizer, Mesh Nebulizer)), By Technology (Manually Operated Inhaler Devices, Digitally Operated Inhaler Devices), By Disease Indication (Asthma, COPD, Pulmonary Arterial Hypertension, Others), and By Regions (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027.

Market Overview:

Respiratory inhalers are medical devices used to deliver medication directly to the lungs of patients with respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. These devices deliver medication in the form of a mist or spray, which is inhaled by the patient. The medication reaches the lungs directly, providing faster relief and reducing the risk of side effects compared to other forms of medication delivery such as pills or injections. There are several types of respiratory inhalers available, including metered-dose inhalers, dry powder inhalers, and nebulizers.

Competitive Landscape:

Major players operating in the global respiratory inhalers market include Teva Pharmaceutical Industries Ltd., PARI Medical Holding, OMRON Healthcare Europe B.V., Merck & Co., Inc., Koninklijke Philips N.V., GlaxoSmithKline plc., Cipla Ltd., Boehringer Ingelheim GmbH, Beximco Pharmaceuticals Ltd., and AstraZeneca plc.

Key Market Drivers:

The global respiratory inhalers market is expected to be driven by various factors, including the increasing prevalence of respiratory diseases, growing demand for convenient and effective drug delivery systems, and rising adoption of combination therapies for respiratory diseases. For instance, according to the National Institutes of Health (NIH), more than 300 million individuals worldwide are living with asthma

Moreover, the increasing geriatric population and rising healthcare expenditure are estimated to further boost the global respiratory inhalers market growth.

Covid-19 Impact Analysis:

The COVID-19 pandemic has significantly impacted the global respiratory inhalers market. The pandemic has led to an increase in the prevalence of respiratory diseases, leading to a surge in demand for respiratory inhalers. For instance, in July 2020, Teva Respiratory introduced the first digital rescue inhaler called albuterol sulfate 117 mcg rescue inhaler. However, the pandemic has also disrupted the global supply chain, leading to a shortage of raw materials and components needed for the production of respiratory inhalers. Moreover, the pandemic has led to delays in clinical trials and regulatory approvals, further impacting the market growth.

Key Takeaways:

·         North America is expected to dominate the growth of the global respiratory inhalers market, owing to factors such as the high prevalence of respiratory diseases, increasing healthcare expenditure, and the presence of key market players. For instance, according to the Asthma and Allergy Foundation of America, over 26 million individuals in the United States have asthma.

·         The Asia Pacific market is estimated to witness significant growth in the global respiratory inhalers market, owing to factors such as the increasing prevalence of respiratory diseases, rising healthcare expenditure, and growing adoption of combination therapies for respiratory diseases. For instance, according to the National Institutes of Health (NIH), around 30 million individuals have asthma.